AstraZeneca contacted Gilead over potential megamerger: Bloomberg News

AstraZeneca contacted Gilead over potential megamerger: Bloomberg News

Reuters  | Jun 07, 2020 15:00

AstraZeneca contacted Gilead over potential megamerger: Bloomberg News

By Paul Sandle and Pamela Barbaglia

LONDON (Reuters) - Britain's AstraZeneca (L:AZN) has approached U.S. rival Gilead Sciences (O:GILD) about a possible merger to form one the world's largest drug companies, Bloomberg News reported on Sunday, citing people familiar with the matter.

Such a deal would unite two of the drugmakers at the forefront of the industry's efforts to fight the new coronavirus and could be politically sensitive as governments seek control over potential vaccines or treatments.

AstraZeneca contacted Gilead last month, but its U.S. rival was not interested in combining with another big pharmaceuticals company, the Bloomberg report https://bloom.bg/3h2GU9e said.

A spokeswoman for AstraZeneca said the company does not comment on rumours or speculation.

Gilead, the world's largest maker of HIV drugs, declined to comment on the report.

If combined, the two companies would have a market capitalisation of about $232 billion, based on Friday's closing share prices.

That would exceed Merck & Co (N:MRK) and Pfizer (N:PFE) at $207 billion and $200 billion respectively.

Two sources familiar with AstraZeneca's thinking questioned the rationale of a tie-up, telling Reuters that Gilead's remdesivir drug for COVID-19 patients was insufficient to justify pursuing a multibillion-dollar deal that would detract from AstraZeneca's work on a coronavirus vaccine.

One of the sources questioned the timing. Given the potential impact a successful vaccine would have on AstraZeneca's share price, it does not need the additional strain of pursuing a record-breaking deal, especially when travel constraints make face-to-face meetings difficult.

While Gilead may look cheap with its price-to-earnings ratio of 12 times and AstraZeneca may be attracted by the potential cost-cutting and decent free cashflow, Jefferies analysts said they do not view a deal as likely.

"We think Gilead believes its HIV business is very underappreciated," they said in a note, adding that the company "would prefer to build value over time and do its own tuck-in deals".

RECORD HIGHS

Gilead's biggest blockbuster drug is HIV drug Biktarvy, with sales of $1.69 billion in the first quarter.

AstraZeneca's top-selling product is its lung cancer drug Tagrisso, which generated first-quarter revenue of $982 million.

Both companies' shares have jumped this year as the healthcare sector has drawn fresh investor interest as drugmakers race to develop treatments and vaccines to counter the pandemic.

AstraZeneca's shares hit record highs in late April while Gilead's stock is up 20% since the start of the year.

Gilead, AstraZeneca and other drugmakers, including Eli Lilly and Co (N:LLY), Pfizer (N:PFE) and Merck & Co (N:MRK), are racing to develop vaccines or treatments for COVID-19, the respiratory illness caused by the novel coronavirus.

More than 6.9 million people have been reported infected with the coronavirus globally and 399,025 have died, a Reuters tally showed on Sunday.

It is unclear whether a vaccine will work, but AstraZeneca's partnership with Oxford University to develop one is among a handful of initiatives U.S. President Donald Trump's COVID task force has backed.

Gilead has also been in the vanguard of COVID-19 treatments.

Its remdesivir antiviral is the first drug to lead to improvement in COVID-19 patients in formal clinical trials.

The drug has been cleared for emergency use in COVID-19 patients in countries including the United States and South Korea and could bring in more than $7 billion in annual sales for by 2022 if governments seek to stockpile it against future outbreaks, SVB Leerink has estimated.

© Reuters. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California

An AstraZeneca-Gilead deal would not be the first big pharma takeover in the past year. U.S. drugmaker Bristol Myers Squibb (N:BMY) completed its $74 billion acquisition of Celgene (NASDAQ:CELG) in November and AbbVie (N:ABBV) is buying Botox maker Allergan (N:AGN) in a $63 billion deal.

Related News

Latest comments

Add a Comment
Please wait a minute before you try to comment again.
Discussion
Write a reply...
Please wait a minute before you try to comment again.

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

English (USA) English (UK) English (India) English (Australia) English (South Africa) English (Philippines) English (Nigeria) Deutsch Español (España) Español (México) Français Italiano Nederlands Português (Portugal) Polski Português (Brasil) Русский Türkçe ‏العربية‏ Ελληνικά Svenska Suomi עברית 日本語 한국어 简体中文 繁體中文 Bahasa Indonesia Bahasa Melayu ไทย Tiếng Việt हिंदी
Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes

+

Download the App

More markets insights, more alerts, more ways to customize assets watchlists only on the App

Investing.com is better on the App!

More content, faster quotes and charts, and a smoother experience is available only on the App.